Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C6H14N2.C2O4.Pt |
Molecular Weight | 397.292 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Pt++].[O-]C(=O)C([O-])=O.N[C@@H]1CCCC[C@H]1N
InChI
InChIKey=ZROHGHOFXNOHSO-BNTLRKBRSA-L
InChI=1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1
Molecular Formula | C6H14N2 |
Molecular Weight | 114.1888 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | Pt |
Molecular Weight | 195.084 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C2O4 |
Molecular Weight | 88.019 |
Charge | -2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Oxaliplatin (brand name Eloxatin), a new generation of platinum derivatives discovered by Prof Kidani in 1976 at Nagoya University in Japan, was licensed-in and developed by Debiopharm. Eloxatin is typically administered in combination with fluorouracil and leucovorin for the adjuvant treatment of stage III colon cancer and for the treatment of advanced carcinoma of the colon or rectum. Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo 1,2-diaminocyclohexane (DACH) platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. Crosslinks are formed between the N7 positions of two adjacent guanines (GG), adjacent adenine-guanines (AG), and guanines separated by an intervening nucleotide (GNG). These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15746072
Curator's Comment: Known to be CNS non-penetrant in nonhuman primates. Human data not available
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2311221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19255091 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ELOXATIN Approved UseOxaliplatin, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for: •adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. •treatment of advanced colorectal cancer. Oxaliplatin injection is a platinum-based drug used in combination with infusional 5-fluorouracil/leucovorin, which is indicated for: •adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. (1) •treatment of advanced colorectal cancer. (1) Launch Date2002 |
|||
Primary | ELOXATIN Approved UseOxaliplatin, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for: •adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. •treatment of advanced colorectal cancer. Oxaliplatin injection is a platinum-based drug used in combination with infusional 5-fluorouracil/leucovorin, which is indicated for: •adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. (1) •treatment of advanced colorectal cancer. (1) Launch Date2002 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.66 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/16395593 |
130 mg/m² 1 times / 3 weeks steady-state, intravenous dose: 130 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
OXALIPLATIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
205.75 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/16395593 |
130 mg/m² 1 times / 3 weeks steady-state, intravenous dose: 130 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
OXALIPLATIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
42.84 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/16395593 |
130 mg/m² 1 times / 3 weeks steady-state, intravenous dose: 130 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
OXALIPLATIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10% |
PLATINUM plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
130 mg/m2 single, intravenous Dose: 130 mg/m2 Route: intravenous Route: single Dose: 130 mg/m2 Sources: |
unhealthy, 56 years |
Disc. AE: Hypersensitivity reaction... AEs leading to discontinuation/dose reduction: Hypersensitivity reaction (1 patient) Sources: |
135 mg/m2 1 times / 4 weeks multiple, intravenous Dose: 135 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 135 mg/m2, 1 times / 4 weeks Sources: |
unhealthy, 57 years (range: 26-81 years) Health Status: unhealthy Age Group: 57 years (range: 26-81 years) Sex: M+F Sources: |
DLT: Neurotoxicity... |
150 mg/m2 1 times / 4 weeks multiple, intravenous Dose: 150 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 150 mg/m2, 1 times / 4 weeks Sources: |
unhealthy, 57 years (range: 26-81 years) Health Status: unhealthy Age Group: 57 years (range: 26-81 years) Sex: M+F Sources: |
DLT: Neurotoxicity... |
175 mg/m2 1 times / 4 weeks multiple, intravenous Dose: 175 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 175 mg/m2, 1 times / 4 weeks Sources: |
unhealthy, 57 years (range: 26-81 years) Health Status: unhealthy Age Group: 57 years (range: 26-81 years) Sex: M+F Sources: |
DLT: Neurotoxicity... |
200 mg/m2 1 times / 4 weeks multiple, intravenous Dose: 200 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 200 mg/m2, 1 times / 4 weeks Sources: |
unhealthy, 57 years (range: 26-81 years) Health Status: unhealthy Age Group: 57 years (range: 26-81 years) Sex: M+F Sources: |
DLT: Neurotoxicity... |
55 mg/m2 multiple, intravenous Dose: 55 mg/m2 Route: intravenous Route: multiple Dose: 55 mg/m2 Sources: |
unhealthy, 58 years |
Disc. AE: Thrombocytopenia... AEs leading to discontinuation/dose reduction: Thrombocytopenia (1 patient) Sources: |
150 mg/m2 1 times / 3 weeks single, intravenous Dose: 150 mg/m2, 1 times / 3 weeks Route: intravenous Route: single Dose: 150 mg/m2, 1 times / 3 weeks Sources: |
unhealthy, 60 years (range: 33-75 years) Health Status: unhealthy Age Group: 60 years (range: 33-75 years) Sex: M+F Sources: |
Disc. AE: Diarrhoea... AEs leading to discontinuation/dose reduction: Diarrhoea (grade 3, 1 patient) Sources: |
725 mg/m2 single, intravenous Dose: 725 mg/m2 Route: intravenous Route: single Dose: 725 mg/m2 Sources: |
unhealthy, 60 years (range: 33-75 years) Health Status: unhealthy Age Group: 60 years (range: 33-75 years) Sex: M+F Sources: |
Disc. AE: Peripheral sensory neuropathy... AEs leading to discontinuation/dose reduction: Peripheral sensory neuropathy (1 patient) Sources: |
900 mg/m2 single, intravenous Dose: 900 mg/m2 Route: intravenous Route: single Dose: 900 mg/m2 Sources: |
unhealthy, 60 years (range: 33-75 years) Health Status: unhealthy Age Group: 60 years (range: 33-75 years) Sex: M+F Sources: |
Disc. AE: Peripheral sensory neuropathy... AEs leading to discontinuation/dose reduction: Peripheral sensory neuropathy (1 patient) Sources: |
925 mg/m2 single, intravenous Dose: 925 mg/m2 Route: intravenous Route: single Dose: 925 mg/m2 Sources: |
unhealthy, 60 years (range: 33-75 years) Health Status: unhealthy Age Group: 60 years (range: 33-75 years) Sex: M+F Sources: |
Disc. AE: Peripheral sensory neuropathy... AEs leading to discontinuation/dose reduction: Peripheral sensory neuropathy (1 patient) Sources: |
130 mg/m2 1 times / 3 weeks multiple, intravenous Dose: 130 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 130 mg/m2, 1 times / 3 weeks Sources: |
unhealthy, 64 years |
Disc. AE: Lhermitte's sign... AEs leading to discontinuation/dose reduction: Lhermitte's sign (1 patient) Sources: |
85 mg/m2 1 times / 2 weeks multiple, intravenous Recommended Dose: 85 mg/m2, 1 times / 2 weeks Route: intravenous Route: multiple Dose: 85 mg/m2, 1 times / 2 weeks Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M Sources: |
Other AEs: Anaphylactic reaction... Other AEs: Anaphylactic reaction Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypersensitivity reaction | 1 patient Disc. AE |
130 mg/m2 single, intravenous Dose: 130 mg/m2 Route: intravenous Route: single Dose: 130 mg/m2 Sources: |
unhealthy, 56 years |
Neurotoxicity | 50% DLT |
135 mg/m2 1 times / 4 weeks multiple, intravenous Dose: 135 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 135 mg/m2, 1 times / 4 weeks Sources: |
unhealthy, 57 years (range: 26-81 years) Health Status: unhealthy Age Group: 57 years (range: 26-81 years) Sex: M+F Sources: |
Neurotoxicity | 64% DLT |
150 mg/m2 1 times / 4 weeks multiple, intravenous Dose: 150 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 150 mg/m2, 1 times / 4 weeks Sources: |
unhealthy, 57 years (range: 26-81 years) Health Status: unhealthy Age Group: 57 years (range: 26-81 years) Sex: M+F Sources: |
Neurotoxicity | 71% DLT |
175 mg/m2 1 times / 4 weeks multiple, intravenous Dose: 175 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 175 mg/m2, 1 times / 4 weeks Sources: |
unhealthy, 57 years (range: 26-81 years) Health Status: unhealthy Age Group: 57 years (range: 26-81 years) Sex: M+F Sources: |
Neurotoxicity | 100% DLT |
200 mg/m2 1 times / 4 weeks multiple, intravenous Dose: 200 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 200 mg/m2, 1 times / 4 weeks Sources: |
unhealthy, 57 years (range: 26-81 years) Health Status: unhealthy Age Group: 57 years (range: 26-81 years) Sex: M+F Sources: |
Thrombocytopenia | 1 patient Disc. AE |
55 mg/m2 multiple, intravenous Dose: 55 mg/m2 Route: intravenous Route: multiple Dose: 55 mg/m2 Sources: |
unhealthy, 58 years |
Diarrhoea | grade 3, 1 patient Disc. AE |
150 mg/m2 1 times / 3 weeks single, intravenous Dose: 150 mg/m2, 1 times / 3 weeks Route: intravenous Route: single Dose: 150 mg/m2, 1 times / 3 weeks Sources: |
unhealthy, 60 years (range: 33-75 years) Health Status: unhealthy Age Group: 60 years (range: 33-75 years) Sex: M+F Sources: |
Peripheral sensory neuropathy | 1 patient Disc. AE |
725 mg/m2 single, intravenous Dose: 725 mg/m2 Route: intravenous Route: single Dose: 725 mg/m2 Sources: |
unhealthy, 60 years (range: 33-75 years) Health Status: unhealthy Age Group: 60 years (range: 33-75 years) Sex: M+F Sources: |
Peripheral sensory neuropathy | 1 patient Disc. AE |
900 mg/m2 single, intravenous Dose: 900 mg/m2 Route: intravenous Route: single Dose: 900 mg/m2 Sources: |
unhealthy, 60 years (range: 33-75 years) Health Status: unhealthy Age Group: 60 years (range: 33-75 years) Sex: M+F Sources: |
Peripheral sensory neuropathy | 1 patient Disc. AE |
925 mg/m2 single, intravenous Dose: 925 mg/m2 Route: intravenous Route: single Dose: 925 mg/m2 Sources: |
unhealthy, 60 years (range: 33-75 years) Health Status: unhealthy Age Group: 60 years (range: 33-75 years) Sex: M+F Sources: |
Lhermitte's sign | 1 patient Disc. AE |
130 mg/m2 1 times / 3 weeks multiple, intravenous Dose: 130 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 130 mg/m2, 1 times / 3 weeks Sources: |
unhealthy, 64 years |
Anaphylactic reaction | 85 mg/m2 1 times / 2 weeks multiple, intravenous Recommended Dose: 85 mg/m2, 1 times / 2 weeks Route: intravenous Route: multiple Dose: 85 mg/m2, 1 times / 2 weeks Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 29.0 |
no | |||
not significant | ||||
not significant | ||||
not significant | ||||
not significant | ||||
not significant | ||||
not significant | ||||
not significant |
PubMed
Title | Date | PubMed |
---|---|---|
Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates. | 2005 Feb 15 |
|
Structural basis for the sequence-dependent effects of platinum-DNA adducts. | 2009 May |
|
Recognition of platinum-DNA damage by poly(ADP-ribose) polymerase-1. | 2010 Jul 27 |
Patents
Sample Use Guides
Adjuvant treatment in patients with stage III colon cancer is recommended for a total of 6 months, i.e., 12 cycles, every 2 weeks, according to the dose schedule described below for previously treated patients with advanced colorectal cancer.
The recommended dose schedule given every two weeks is as follows:
Day 1: ELOXATIN 85 mg/m2 IV infusion in 250-500 mL D5W and leucovorin 200 mg/m2 IV infusion in D5W both given over 120 minutes at the same time in separate bags using a Y-line, followed by 5-FU 400 mg/m2 IV bolus given over 2-4 minutes, followed by 5-FU 600 mg/m2 IV infusion in 500 mL D5W (recommended) as a 22-hour continuous infusion. Day 2: Leucovorin 200 mg/m2 IV infusion over 120 minutes, followed by 5-FU 400 mg/m2 IV bolus given over 2-4 minutes, followed by 5-FU 600 mg/m2 IV infusion in 500 mL D5W (recommended) as a 22-hour continuous infusion.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11062751
The anti-proliferative effects of oxaliplatin in human HT29 and NMG64/84 colon and COLO-357 MIA PaCa-2 and PMH2/89 pancreatic cancer cell lines and in fresh liver metastases from patients with colorectal and pancreatic cancer were investigated using the human tumor colony forming assay. Oxaliplatin significantly inhibited the colony formation in all cell lines in a concentration- and time-dependent manner. All liver tumors displayed a significant concentration-dependent inhibition of colony formation after exposure to oxaliplatin for 2 hours. The IC50 of oxaliplatin of 9 of the 10 tumors was < 10 micrograms/ml.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 08:46:50 GMT 2025
by
admin
on
Wed Apr 02 08:46:50 GMT 2025
|
Record UNII |
04ZR38536J
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
561716
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
||
|
WHO-VATC |
QL01XA03
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
||
|
WHO-ATC |
L01XA03
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
||
|
FDA ORPHAN DRUG |
560816
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
||
|
FDA ORPHAN DRUG |
605617
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
||
|
LIVERTOX |
NBK548456
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
||
|
NCI_THESAURUS |
C1450
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
||
|
NDF-RT |
N0000175073
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
||
|
NDF-RT |
N0000175413
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
||
|
FDA ORPHAN DRUG |
69492
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6012
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
PRIMARY | |||
|
C030110
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
PRIMARY | |||
|
DB00526
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
PRIMARY | |||
|
31941
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
PRIMARY | |||
|
04ZR38536J
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
PRIMARY | |||
|
7433
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
PRIMARY | |||
|
4210
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
PRIMARY | |||
|
1481204
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
PRIMARY | |||
|
61825-94-3
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
PRIMARY | |||
|
m8281
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID0036760
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
PRIMARY | |||
|
04ZR38536J
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
PRIMARY | |||
|
100000085171
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
PRIMARY | |||
|
SUB09490MIG
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
PRIMARY | |||
|
266046
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
PRIMARY | |||
|
32592
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
PRIMARY | RxNorm | ||
|
Oxaliplatin
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
PRIMARY | |||
|
CHEMBL414804
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
PRIMARY | |||
|
OXALIPLATIN
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
PRIMARY | |||
|
C1181
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
PRIMARY | |||
|
KK-45
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
PRIMARY | |||
|
9887054
Created by
admin on Wed Apr 02 08:46:50 GMT 2025 , Edited by admin on Wed Apr 02 08:46:50 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
LABELED -> NON-LABELED |
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
EP
|
||
|
TRANSPORTER -> SUBSTRATE |
MAY BE RESPONSIBLE FOR THE ACTIVITY OF OXALIPLATIN AGAINST against colorectal tumors
MAJOR
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
TRANSPORTER -> SUBSTRATE |
MAY BE RESPONSIBLE FOR THE ACTIVITY OF OXALIPLATIN AGAINST against colorectal tumors
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
limites not given
EP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|